About Nocion Therapeutics

Nocion Therapeutics develops nocions, small molecules that selectively target inflamed nociceptors through large-pore channels to inhibit sodium channels, providing sustained relief from conditions such as chronic cough, pain, and itch. This targeted approach minimizes off-target effects and enhances potency compared to traditional sodium channel blockers, addressing significant unmet medical needs in neurogenic inflammation.

```xml <problem> Current treatments for conditions driven by neurogenic inflammation, such as chronic cough, pain, and itch, often lack specificity, leading to off-target effects and limited efficacy. Traditional sodium channel blockers can affect a wide range of neurons, resulting in undesired side effects and reduced potency. </problem> <solution> Nocion Therapeutics is developing a novel class of therapeutics called "nocions" designed to selectively target inflamed nociceptors, the sensory neurons responsible for pain and inflammation. Nocions are small molecules that enter activated nociceptors through large-pore channels and inhibit sodium channels within these cells. This targeted approach aims to provide sustained relief from conditions like chronic cough, itch, and pain while minimizing off-target effects on other neurons. By selectively acting on inflamed nociceptors, Nocion's technology offers the potential for greater potency, longer half-life, and reduced risk of side effects compared to traditional sodium channel blockers. The company's platform is based on the well-understood physiology of nociceptors and the unique properties of large-pore channels that open in response to external stimuli. </solution> <features> - Nocions selectively enter inflamed nociceptors via large-pore channels. - Once inside, nocions block all sodium channels, inhibiting neuronal firing. - The charged nature of nocions prevents them from entering non-nociceptors or redistributing to local cells. - Topical administration allows for low systemic exposure. - Potential for greater potency and longer half-life compared to traditional sodium channel blockers. - Reduced risk of off-target activity and undesired side effects. - Non-CNS, non-opiate treatment of pain. </features> <target_audience> The primary target audience includes patients suffering from chronic cough, various pain conditions (acute post-op pain, burns, neuropathic pain, etc.), itch (atopic dermatitis, pruritus, etc.) and inflammatory conditions affecting various organ systems (pulmonology, gynecology/urology, dermatology, gastroenterology, ophthalmology). </target_audience> ```

What does Nocion Therapeutics do?

Where is Nocion Therapeutics located?

Nocion Therapeutics is based in Cambridge, United Kingdom.

When was Nocion Therapeutics founded?

Nocion Therapeutics was founded in 2017.

How much funding has Nocion Therapeutics raised?

Nocion Therapeutics has raised 122000000.

Location

Cambridge, United Kingdom

Founded

2017

Funding

122000000

Employees

19 employees

Major Investors

Monograph Capital, Arkin Holdings

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Nocion Therapeutics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

nociontx.com 2K+

Crunchbase

Founded 2017 – Cambridge, United Kingdom

Funding

Estimated Funding

$100M+

Major Investors

Monograph Capital, Arkin Holdings

Team (15+)

No team information available.

Company Description

Problem

Current treatments for conditions driven by neurogenic inflammation, such as chronic cough, pain, and itch, often lack specificity, leading to off-target effects and limited efficacy. Traditional sodium channel blockers can affect a wide range of neurons, resulting in undesired side effects and reduced potency.

Solution

Nocion Therapeutics is developing a novel class of therapeutics called "nocions" designed to selectively target inflamed nociceptors, the sensory neurons responsible for pain and inflammation. Nocions are small molecules that enter activated nociceptors through large-pore channels and inhibit sodium channels within these cells. This targeted approach aims to provide sustained relief from conditions like chronic cough, itch, and pain while minimizing off-target effects on other neurons. By selectively acting on inflamed nociceptors, Nocion's technology offers the potential for greater potency, longer half-life, and reduced risk of side effects compared to traditional sodium channel blockers. The company's platform is based on the well-understood physiology of nociceptors and the unique properties of large-pore channels that open in response to external stimuli.

Features

Nocions selectively enter inflamed nociceptors via large-pore channels.

Once inside, nocions block all sodium channels, inhibiting neuronal firing.

The charged nature of nocions prevents them from entering non-nociceptors or redistributing to local cells.

Topical administration allows for low systemic exposure.

Potential for greater potency and longer half-life compared to traditional sodium channel blockers.

Reduced risk of off-target activity and undesired side effects.

Non-CNS, non-opiate treatment of pain.

Target Audience

The primary target audience includes patients suffering from chronic cough, various pain conditions (acute post-op pain, burns, neuropathic pain, etc.), itch (atopic dermatitis, pruritus, etc.) and inflammatory conditions affecting various organ systems (pulmonology, gynecology/urology, dermatology, gastroenterology, ophthalmology).